Krystal Biotech (KRYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrea Newkirk from Goldman Sachs maintained a Buy rating on the stock and has a $194.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Andrea Newkirk’s rating is based on Krystal Biotech’s promising growth prospects and strategic initiatives. The company has shown confidence in the launch of Vyjuvek, aiming to reach a significant number of identified patients. Efforts to expand the sales team and the potential for self-/caregiver administration in the US are expected to address any delays in treatment conversion time.
Additionally, Krystal Biotech is exploring growth opportunities in its pipeline, including advancements in cystic fibrosis and ophthalmic lesions, which present attractive commercial opportunities. The company’s focus on differentiation in efficacy, dosing, and tolerability compared to competitors, alongside its strategic approach in oncology, further supports the Buy rating.
In another report released on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.